175 related articles for article (PubMed ID: 1699752)
1. Tumor markers and oncogene expression in thyroid cancer using biochemical and immunohistochemical studies.
Hashimoto T; Matsubara F; Mizukami Y; Miyazaki I; Michigishi T; Yanaihara N
Endocrinol Jpn; 1990 Apr; 37(2):247-54. PubMed ID: 1699752
[TBL] [Abstract][Full Text] [Related]
2. Expression of ras oncogene p21 antigen in normal and proliferative thyroid tissues.
Johnson TL; Lloyd RV; Thor A
Am J Pathol; 1987 Apr; 127(1):60-5. PubMed ID: 3105323
[TBL] [Abstract][Full Text] [Related]
3. Tumor markers in patients with chronic renal failure.
Filella X; Cases A; Molina R; Jo J; Bedini JL; Revert L; Ballesta AM
Int J Biol Markers; 1990; 5(2):85-8. PubMed ID: 1704405
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical demonstration of thyroglobulin in thyroid pathology.
Stefăneanu L; Simionescu L; Aman E; Taşcă C
Endocrinologie; 1984; 22(1):55-9. PubMed ID: 6369503
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of squamous cell carcinoma antigen in cancer of the human uterine cervix. Comparison with CEA and CA-125.
Verlooy H; Devos P; Janssens J; Mortelmans L; Gerits M; Bonte J; De Roo M
Gynecol Obstet Invest; 1991; 32(1):55-8. PubMed ID: 1765320
[TBL] [Abstract][Full Text] [Related]
6. Effect of hemodialysis on the concentration of the seven tumor markers carcinoembryonic antigen, alpha-fetoprotein, squamous cell carcinoma-related antigen, neuron-specific enolase, CA 125, CA 19-9 and CA 15-3 in uremic patients.
Odagiri E; Jibiki K; Takeda M; Sugimura H; Iwachika C; Abe Y; Kihara K; Kihara Y; Itou M; Nomura T
Am J Nephrol; 1991; 11(5):363-8. PubMed ID: 1725572
[TBL] [Abstract][Full Text] [Related]
7. C cell carcinoma of the thyroid. Follicular variant.
Lertprasertsuke N; Kakudo K; Nakamura A; Tada N; Osamura Y; Watanabe K; Kubota M
Acta Pathol Jpn; 1989 Jun; 39(6):393-9. PubMed ID: 2481937
[TBL] [Abstract][Full Text] [Related]
8. Tumor markers in chronic renal failure and hemodialysis patients.
Cases A; Filella X; Molina R; Ballesta AM; Lopez-Pedret J; Revert L
Nephron; 1991; 57(2):183-6. PubMed ID: 2020345
[TBL] [Abstract][Full Text] [Related]
9. Epithelial markers in thyroid carcinoma: an immunoperoxidase study.
Wilson NW; Pambakian H; Richardson TC; Stokoe MR; Makin CA; Heyderman E
Histopathology; 1986 Aug; 10(8):815-29. PubMed ID: 2428725
[TBL] [Abstract][Full Text] [Related]
10. Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer.
Jing JX; Wang Y; Xu XQ; Sun T; Tian BG; Du LL; Zhao XW; Han CZ
Asian Pac J Cancer Prev; 2014; 15(23):10267-72. PubMed ID: 25556459
[TBL] [Abstract][Full Text] [Related]
11. Serum and tissue levels of CEA, TPA, CA 125 and CA 15.3 in patients with lung cancer.
Macchia V; Paduano D; Di Carlo A; Mariano A; Cecere C; Ferrante G
Int J Biol Markers; 1993; 8(4):215-20. PubMed ID: 8138661
[TBL] [Abstract][Full Text] [Related]
12. CA 19-9 expression in subacute (de Quervain's) thyroiditis: an immunohistochemical study.
Schmid KW; Ofner C; Ramsauer T; Hittmair A; Tötsch M; Ladurner D; Böcker W
Mod Pathol; 1992 May; 5(3):268-72. PubMed ID: 1495932
[TBL] [Abstract][Full Text] [Related]
13. Comparative studies of CAM 123-6 and carcinoembryonic antigen for the serological detection of pulmonary adenocarcinoma.
Kohno N; Hirasawa Y; Kondo K; Fujioka S; Fujino S; Abe M; Yokoyama A; Hiwada K; Watanabe K; Nishimura J
Cancer Detect Prev; 1997; 21(2):124-8. PubMed ID: 9101072
[TBL] [Abstract][Full Text] [Related]
14. Expression of p63 in papillary thyroid carcinoma and in Hashimoto's thyroiditis: a pathobiologic link?
Unger P; Ewart M; Wang BY; Gan L; Kohtz DS; Burstein DE
Hum Pathol; 2003 Aug; 34(8):764-9. PubMed ID: 14506636
[TBL] [Abstract][Full Text] [Related]
15. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
16. Disparity between tissue and serum calcitonin and carcinoembryonic antigen in a patient with medullary thyroid carcinoma.
Alapat DV; Ain KB; Sloan DA; Monaghan KG; Karabakhtsian RG
Endocrine; 2011 Apr; 39(2):148-52. PubMed ID: 21243446
[TBL] [Abstract][Full Text] [Related]
17. The lack of utility of a tumor marker panel in head and neck carcinoma. Squamous cell carcinoma antigen, carcinoembryonic antigen, lipid-associated sialic acid, and CA-125.
Straka MB; Wagner RL; Johnson JT; Kachman KK; Eibling DE
Arch Otolaryngol Head Neck Surg; 1992 Aug; 118(8):802-5. PubMed ID: 1642830
[TBL] [Abstract][Full Text] [Related]
18. [Bcl-2 proto-oncogene expression in neoplastic and non neoplastic thyroid tissue].
Branet F; Caron P; Camallières M; Selves J; Brousset P
Bull Cancer; 1996 Mar; 83(3):213-7. PubMed ID: 8695923
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma.
Tabata T; Takeshima N; Tanaka N; Hirai Y; Hasumi K
Tumour Biol; 2000; 21(6):375-80. PubMed ID: 11006578
[TBL] [Abstract][Full Text] [Related]
20. Role of serum thyroglobulin in the pre-operative evaluation of follicular thyroid tumours.
Hocevar M; Auersperg M
Eur J Surg Oncol; 1998 Dec; 24(6):553-7. PubMed ID: 9870733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
